|
May 11
|
The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically
|
|
May 9
|
Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)
|
|
May 8
|
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
|
|
May 7
|
Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts
|
|
May 7
|
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
|
|
May 1
|
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
|
|
Apr 29
|
Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?
|
|
Apr 9
|
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
|
|
Mar 29
|
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
|
|
Mar 28
|
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
|
|
Mar 19
|
Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%
|
|
Feb 1
|
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
|
|
Jan 26
|
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
|
|
Jan 11
|
40 Cities with the Lowest Life Expectancy in the US
|
|
Jan 8
|
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
|
|
Jan 2
|
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
|
|
Dec 26
|
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
|
|
Dec 22
|
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
|
|
Dec 22
|
40 Cities with the Highest Life Expectancy in the US
|
|
Dec 21
|
Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect?
|